❤️30 REASONS TO LOVE BIEL❤️
1. It's a real company with real products.
2. The company is not burning $$$ millions every quarter trying to get a product through the FDA wringer. They've accomplished FDA clearance (5) already.
3. The company is very close to profitability every quarter. BIEL will likely be profitable soon, it not already (a $400K quarter should do it).
4. There is no toxic debt. The company is not sinking under death spiral financing.
5. Actipatch has thousands of excellent, mostly 5-star customer reviews.
6. The $40 million tax-loss carry forward will make the first $40 million in profits tax free and accelerate the path to profitability.
7. $800k annual revenue gets the pps out of the trips.
8. Technical indicators (Golden Cross, Blue Sky Breakout, etc.) turning positive. Every bull run starts with this.
9. Bare bones expenses: about $750k/year for GENERAL AND ADMIN EXPENSES (salaries, utilities, R&D, Advertising, etc) with a burn rate of about $220k/year for Other Gen and Admin Expenses.
10. New utility patent (pending) for chronic pain inflammation (vagus nerve) - HUGE.
11. Actipatch will be a Standard of Care product.
12. They have 5 FDA clearances with more pending.
13. Insurance coverage is expanding - currently covered by the UK National Health Service (and Taiwan?).
14. Been in business for over 20 years and never reverse split.
15. Accepted for use by the Veterans Administration.
16. Rapidly expanding in the veterinary/pet market.
17. New contract/partner rumors swirling.
18. Amazon/Apple type of return on investment (ROI) very possible.
19. Fed forecast to cut interest rates five times this year, which greatly benefits OTC stocks like BIEL.
20. BIEL goes viral at pps = .006.
21. A new distribution partner for the USA will be announced soon. The last time this happened (2021) BIEL surged 1,600%.
22. BIEL is optimizing the Netflix business model.
23. PPS = .02: 200,000% increase (equivalent to Apple, Amazon and Netflix from their low point). Requires $5 million profit (P/E = 100).
24. PPS = .10: Requires $25 million profit (P/E = 100).
25. The potential is mind-boggling - especially if Actipatch is identified as a "wellness product" for the applications not currently covered by the FDA clearances (menstrual, depression, migraines, restless leg, etc.).
26. The Actipatch/RecoveryRX has HUGE market potential - essentially every human on the planet and RecoveryRX Veterinary for their pets!
27. The higher margin RecoveryRX is available by prescription.
28. RECOVERYRX-VETERINARY could be a GOLDMINE!
29. BIEL COULD HIT COPPER IN THE "BLINK OF AN EYE"!
30. See 1 - 29!
1. It's a real company with real products.
2. The company is not burning $$$ millions every quarter trying to get a product through the FDA wringer. They've accomplished FDA clearance (5) already.
3. The company is very close to profitability every quarter. BIEL will likely be profitable soon, it not already (a $400K quarter should do it).
4. There is no toxic debt. The company is not sinking under death spiral financing.
5. Actipatch has thousands of excellent, mostly 5-star customer reviews.
6. The $40 million tax-loss carry forward will make the first $40 million in profits tax free and accelerate the path to profitability.
7. $800k annual revenue gets the pps out of the trips.
8. Technical indicators (Golden Cross, Blue Sky Breakout, etc.) turning positive. Every bull run starts with this.
9. Bare bones expenses: about $750k/year for GENERAL AND ADMIN EXPENSES (salaries, utilities, R&D, Advertising, etc) with a burn rate of about $220k/year for Other Gen and Admin Expenses.
10. New utility patent (pending) for chronic pain inflammation (vagus nerve) - HUGE.
11. Actipatch will be a Standard of Care product.
12. They have 5 FDA clearances with more pending.
13. Insurance coverage is expanding - currently covered by the UK National Health Service (and Taiwan?).
14. Been in business for over 20 years and never reverse split.
15. Accepted for use by the Veterans Administration.
16. Rapidly expanding in the veterinary/pet market.
17. New contract/partner rumors swirling.
18. Amazon/Apple type of return on investment (ROI) very possible.
19. Fed forecast to cut interest rates five times this year, which greatly benefits OTC stocks like BIEL.
20. BIEL goes viral at pps = .006.
21. A new distribution partner for the USA will be announced soon. The last time this happened (2021) BIEL surged 1,600%.
22. BIEL is optimizing the Netflix business model.
23. PPS = .02: 200,000% increase (equivalent to Apple, Amazon and Netflix from their low point). Requires $5 million profit (P/E = 100).
24. PPS = .10: Requires $25 million profit (P/E = 100).
25. The potential is mind-boggling - especially if Actipatch is identified as a "wellness product" for the applications not currently covered by the FDA clearances (menstrual, depression, migraines, restless leg, etc.).
26. The Actipatch/RecoveryRX has HUGE market potential - essentially every human on the planet and RecoveryRX Veterinary for their pets!
27. The higher margin RecoveryRX is available by prescription.
28. RECOVERYRX-VETERINARY could be a GOLDMINE!
29. BIEL COULD HIT COPPER IN THE "BLINK OF AN EYE"!
30. See 1 - 29!
2
